Staph Bacteria Use a Pump to Resist the Body's Antimicrobial Peptides — and This Resistance Drives Real Infections

The S. aureus Pmt ABC transporter defends bacteria from killing by important human AMPs and from elimination by human neutrophils. Pmt contributes to virulence during skin infection in an AMP-dependent manner — when AMP activity was removed from the experimental system, the virulence advantage of Pmt was eliminated. This provides the first direct in vivo evidence that antimicrobial peptide resistance per se is important during bacterial infection, not just in laboratory conditions.

Researchers compared wild-type S. aureus to Pmt-deficient mutants for: susceptibility to human AMPs (in vitro killing assays), survival against human neutrophils, and virulence in mouse skin infection models. To prove the effect was specifically AMP-dependent, they performed skin infections under conditions where AMP activity was absent, showing that the virulence advantage of Pmt disappeared — confirming the causal link between AMP resistance and infection outcome.

Antimicrobial peptides are frequently proposed as alternatives to conventional antibiotics, but a major concern has been whether bacteria could evolve resistance that undermines their therapeutic potential. This study shows that AMP resistance mechanisms not only exist but are already clinically important — S. aureus uses them to cause infections. This has implications for both understanding staph pathogenesis and designing AMP-based therapies that can overcome resistance.

The antimicrobial peptide field has often argued that bacteria are unlikely to develop significant resistance to AMPs because they've coexisted with these peptides for millions of years. This study challenges that narrative by showing that AMP resistance mechanisms are not only present but actively contribute to infection. This is crucial context for developing AMP-based therapeutics — effective clinical peptides will need to be designed to evade bacterial resistance mechanisms like Pmt.

The study focused on one resistance mechanism (Pmt transporter) in one bacterial species (S. aureus) during one type of infection (skin). Other AMP resistance mechanisms may operate differently. The mouse skin infection model may not fully represent the complexity of human staph infections. The specific AMPs involved in the Pmt-dependent virulence were not individually identified. Whether Pmt-mediated resistance could be overcome by modified AMPs was not tested.